Menu
← Oncology Approval Tracker
FDA DECISION ·
Verzenio + endocrine therapy
abemaciclib with tamoxifen or an aromatase inhibitor · Eli Lilly
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with node-positive HR-positive, HER2-negative early breast cancer at high risk of recurrence and Ki-67 of at least 20% by an FDA-approved test, in combination with endocrine therapy. FDA later removed the Ki-67 requirement.
LAMPGEN ANALYSIS
Why it matters
The 2021 adjuvant action used a Ki-67 threshold that changed in 2023.
What research teams should watch
Preserve the pathology, nodal risk features, assay result and label version when analyzing historical eligibility.
PRIMARY RECORDS